PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Cited by (285)

Items 101–200 of 285

1. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
   Alessandra Fabi, Paola Malaguti, Sabrina Vari, Francesco Cognetti · 2016 · Journal of Experimental & Clinical Cancer Research
2. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
   Paolo Giovanni Nuciforo, Claudia Monica Aura, Eileen McCormick Holmes, Ludmila Prudkin, José Jimenez, P. Martinez, Helene Ameels, Lorena de la Peña, C. Ellis, Holger Eidtmann et al. · 2015 · Annals of Oncology
3. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
   Shima Moradi‐Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian, Leila Farahmand · 2018 · Journal of Pharmacy and Pharmacology
4. Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer
   Paolo Tarantino, Giuseppe Curigliano, Heather A. Parsons, NU Lin, Ian E. Krop, Elizabeth A. Mittendorf, Adrienne Waks, Eric P. Winer, Sara M. Tolaney · 2022 · JAMA Oncology
5. PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
   Xianglan Zhang, Ji Soo Park, Kyu Hyun Park, Ki Hyang Kim, Minkyu Jung, Hyun Cheol Chung, Sun Young Rha, Hyo Song Kim · 2014 · Oncology
6. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria
   Alexandre Harlé, Maëva Lion, Nicolas Lozano, Marie Husson, Valentin Harter, Pascal Génin, Jean‐Louis Merlin · 2013 · Oncology Reports
7. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases
   Gabriela Paroni, Marco Bolis, Adriana Zanetti, Paolo Ubezio, Kristian Helin, Peter Staller, Lars Ole Gerlach, Maddalena Fratelli, Richard M. Neve, Mineko Terao et al. · 2018 · Oncogene
8. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
   Olivia Leblanc, Sophie Vacher, Charlotte Lecerf, Emmanuelle Jeannot, Jerzy Klijanienko, Frédérique Berger, Caroline Hoffmann, Valentin Calugaru, Nathalie Badois, Anne Chilles et al. · 2020 · Cancer Biology and Medicine
9. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer
   Rashmi Krishna Murthy, Ankur Varma, Priyankana Mishra, Kenneth R. Hess, Elliana J. Young, James Lee Murray, Kimberly Higginbotham Koenig, Stacy L. Moulder, Amal Melhem‐Bertrandt, Sharon Hermes Giordano et al. · 2014 · Cancer
10. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab
    Francisco J. Esteva, Justin Stebbing, Rebecca N. Wood-Horrall, Peter J. Winkle, Sungyoung Lee, Sang Joon Lee · 2018 · Cancer Chemotherapy and Pharmacology
11. An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
    Ahmed M. Elshazly, David A. Gewirtz · 2022 · Cancer Drug Resistance
12. Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
    Alexandre André Balieiro Anastácio da Costa, Felipe D’Almeida Costa, Adriana R. Ribeiro, Andréia P. Guimarães, Ludmilla Thomé Domingos Chinen, Clovis A. Pinto Lopes, Vladmir Cláudio Cordeiro de Lima · 2014 · International Journal of Clinical Oncology
13. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis
    Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Mubarak M. Al-Mansour, Meteb Al‐Foheidi · 2015 · Breast Cancer Research and Treatment
14. Genetically engineered mouse models of PI3K signaling in breast cancer
    Sjoerd Klarenbeek, Martine H. van Miltenburg, Jos Jonkers · 2013 · Molecular Oncology
15. A soluble form of GAS1 inhibits tumor growth and angiogenesis in a triple negative breast cancer model
    Adriana Jiménez, Adolfo López-Ornelas, Enrique Estudillo, Lorenza González‐Mariscal, Rosa O. González, José Segovia · 2014 · Experimental Cell Research
16. The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer
    Krishnaswamy Kannan, Alagarsamy Srinivasan, Aarthi Kannan, Nawab Ali · 2025 · Cancers
17. “Omics” of HER2-Positive Breast Cancer
    Valentina Bravatà, Francesco Paolo Cammarata, Giusi Irma Forte, Luigi Minafra · 2013 · OMICS A Journal of Integrative Biology
18. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
    Masakazu Toi, Zhimin Shao, Sara Alsterlind Hurvitz, Ling‐Ming Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Jifeng Feng, Binghe Xu, Xiaojia Wang et al. · 2017 · Breast Cancer Research
19. Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Yi Ding, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin Lin, Gehao Liang, Lifeng Yuan, Handan Xiang, Junying Chen et al. · 2018 · Nature Communications
20. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway
    Hui Yao, Song Su, Dong Xia, Mingming Wang, Zonglin Li, Wangsheng Chen, Lei Ren, Liang Xu · 2018 · Biomedicine & Pharmacotherapy
21. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
    Lu Yang, Yun Li, Arup Bhattacharya, Yuesheng Zhang · 2019 · Science Translational Medicine
22. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Amy Jo Chien, Alyson Cockerill, Craig Fancourt, Emmett V. Schmidt, Mark M. Moasser, Hope S. Rugo, Michelle Melisko, Andrew H. Ko, Robin Kate Kelley, Wolfgang Michael Korn et al. · 2016 · Breast Cancer Research and Treatment
23. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
    Luca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, Carmine Valenza, Lorenzo Guidi, Carmen Belli, Elias Alexandros Kotteas, Antonio Marra, Aleix Prat, Nicola Fusco et al. · 2024 · Cancer Treatment Reviews
24. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines
    Juan Carlos Roa, Pamela Leal, Patricia García, Alejandra Sandoval, Kurt Buchegger, Óscar Tapia, Helga L. Weber · 2013 · OncoTargets and Therapy
25. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
    Nandini Dey, Yuliang Sun, Jennifer H. Carlson, Huixia Wu, Xiaogian Lin, Brian R Leyland-Jones, Pradip K. De · 2016 · PubMed Central
26. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies
    Yongming Xi, Yan Chen · 2015 · Journal of Cellular Biochemistry
27. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
    Windy Marie Dean-Colomb, Kenneth R. Hess, Elliana J. Young, Terrie G. Gornet, Beverly Carol Handy, Stacy L. Moulder, Nuhad K. Ibrahim, Lajos Pusztai, Daniel J. Booser, Vicente Valero et al. · 2012 · Breast Cancer Research and Treatment
28. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
    Andreas W. Machl, Erik Wilker, Hui Tian, Xiaohong Liu, Patricia E. Schroeder, Anderson Clark, Bayard R. Huck · 2016 · PubMed Central
29. Optimal Management of Early and Advanced HER2 Breast Cancer
    Sara Alsterlind Hurvitz, Karen A. Gelmon, Sara M. Tolaney · 2017 · American Society of Clinical Oncology Educational Book
30. An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
    Aiko Sueta, Yutaka Yamamoto, Mutsuko Yamamoto‐Ibusuki, Mitsuhiro Hayashi, Takashi Takeshita, Satoko Yamamoto, Hirotaka Iwase · 2014 · PLoS ONE
31. Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy
    Muhan Chen, Dawid Grzegorz Nowak, Lloyd C. Trotman · 2014 · Clinical Cancer Research
32. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
    Binghe Xu, Zhongzhen Guan, Zhenzhou Shen, Zhongshen Tong, Zefei Jiang, Junlan Yang, Michelle DeSilvio, Mark Russo, Meggan Leigh, Catherine Elizabeth Ellis · 2014 · Breast Cancer Research
33. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer
    José Alejandro Pérez Fidalgo, Carmen Criscitiello, Eva Carrasco, Meredith M. Regan, Angelo Di Leo, Karin Ribi, Virginie Sarah Adam, Philippe Lucien Bedard · 2022 · Future Oncology
34. PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
    Ju Won Kim, Ah Reum Lim, Ji Young You, Jung‐Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Kyong Hwa Park · 2022 · Cancer Research and Treatment
35. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
    Mattia Barbareschi, Lucia Veronica Cuorvo, Salvatore Girlando, Emma Bragantini, Claudio Eccher, Elena Leonardi, Antonella Ferro, Alessia Caldara, Renza Triolo, Chiara Cantaloni et al. · 2012 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
36. The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe
    Richard J. Epstein · 2013 · Frontiers in Oncology
37. Implications of genomic instability in the diagnosis and treatment of breast cancer
    Emilia Wiecheć · 2011 · Expert Review of Molecular Diagnostics
38. BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
    Satyajit Patra, Vanesa Young, Leslie Llewellyn, Jitendra Narayan Senapati, Jesil Mathew · 2017 · PubMed Central
39. HetRCNA: A Novel Method to Identify Recurrent Copy Number Alternations from Heterogeneous Tumor Samples Based on Matrix Decomposition Framework
    Jianing Xi, Ao Li, Minghui Wang · 2018 · IEEE Transactions on Computational Biology and Bioinformatics
40. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
    Qian Zhang, Jian Chen, 俞晓立, Gang Cai, 杨兆知, Lu Cao, Chaosu Hu, 郭小毛, Jing Sun, Jiayi Chen · 2015 · Breast Cancer
41. MiR-429 Regulated by Endothelial Monocyte Activating Polypeptide-II (EMAP-II) Influences Blood-Tumor Barrier Permeability by Inhibiting the Expressions of ZO-1, Occludin and Claudin-5
    Liangyu Chen, Yixue Xue, Jian Zheng, Xiaobai Liu, Jing Liu, Jiajia Chen, Zhen Li, Zhuo Xi, Hao Wei Teng, Ping Wang et al. · 2018 · Frontiers in Molecular Neuroscience
42. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
    Carmen Criscitiello, Giulia Viale, Giuseppe Curigliano, Aron Goldhirsch · 2018 · Breast Cancer Targets and Therapy
43. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells
    Ning-Ning Zhou, Jun Tang, Wen-Dan Chen, Gong‐Kan Feng, Bin-Fen Xie, Zong Chao Liu, Dajun Yang, Xiao‐Feng Zhu · 2012 · Life Sciences
44. Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
    Rita Nahta · 2012 · Chemotherapy Research and Practice
45. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy
    Yidong Zhou, Changjun Wang, Hanjiang Zhu, Yan Lin, Bo Pan, Xiaohui Zhang, Xin Huang, Qianqian Xu, Yali Xu, Qiang Sun · 2016 · PLoS ONE
46. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
    Alberto Ocaña, Marta Gil-Martín, Miguel Martín, Federico Rojo, Silvia Antolín, Ángel Guerrero, José Manuel Trigo, Montserrat Muñoz-Mateu, Atanasio Pandiella, Núria Gonzalo et al. · 2017 · Oncotarget
47. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer
    James E. Korkola, Eric Andrew Collisson, Laura M. Heiser, Chris J. Oates, Nora Bayani, Sleiman M. Itani, Amanda M. Esch, Wallace Thompson, Obi L. Griffith, Nicholas J. Wang et al. · 2015 · PLoS ONE
48. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
    Dong‐Hoe Koo, Hee Jin Lee, Jin Hee Ahn, Dok Hyun Yoon, Sung‐Bae Kim, Gyungyub Gong, Byung Ho Son, Sei Hyun Ahn, Kyung Hae Jung · 2015 · Tumor Biology
49. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
    Taylor Fulton-Ward, Gary Middleton · 2023 · Annals of Oncology
50. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer
    George Somlo, Cynthia L. Martel, Sean K. Lau, Paul Henry Frankel, Christopher Ruel, Lei Gu, Arti Hurria, Cathie T. Chung, T. Luu, Robert J. Morgan et al. · 2011 · Breast Cancer Research and Treatment
51. Annexin A4-nuclear factor-κB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer
    Houshan Yao, Chang Sun, Xinxing Li, Yi Wang, Kaizhou Jin, Xiaoping Zhang, Zhiqian Hu · 2016 · Scientific Reports
52. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
    Maki Tanioka, Kazuko Sakai, Tamotsu Sudo, T. Sakuma, Kazuyoshi Kajimoto, Koichi Hirokaga, Shintaro Takao, Shunichi Negoro, Hironobu Minami, Kazuhiko Nakagawa et al. · 2014 · Breast Cancer Research and Treatment
53. Genomic Markers of Resistance to Targeted Treatments in Gastric Cancer: Potential New Treatment Strategies
    Alessandra Raimondi, Federico Nichetti, Giorgia Peverelli, Maria Di Bartolomeo, Filippo de Braud, Filippo Pietrantonio · 2018 · Pharmacogenomics
54. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
    Peter Grell, Pavel Fabián, Marta Khoylou, Lenka Radová, Ondřej Slabý, Roman Hrstka, Rostislav Vyzula, Marián Hajdúch, Marek Svoboda · 2012 · International Journal of Oncology
55. Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process
    Tushar Baran Deb, Annie Zuo, Robert J. Barndt, Surojeet Sengupta, Radmila Janković, Michael D. Johnson · 2015 · Breast Cancer Research and Treatment
56. PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical Studies
    Megan L. Troxell · 2012 · Journal of Clinical & Experimental Pathology
57. Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting
    Agnieszka Adamczyk, Aleksandra Grela-Wojewoda, Małgorzata Domagała-Haduch, Aleksandra Ambicka, Agnieszka Harazin-Lechowska, Anna Janecka, Ida Cedrych, Kaja Majchrzyk, Anna Kruczak, Janusz Ryś et al. · 2016 · Journal of Cancer
58. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer
    Marie Colombe Agahozo, Anieta M. Sieuwerts, Shusma C. Doebar, Esther I. Verhoef, Corine M. Beaufort, Kirsten Ruigrok-Ritstier, Vanja de Weerd, Hein F.B.M. Sleddens, Winand N.M. Dinjens, John W.M. Martens et al. · 2019 · Endocrine Related Cancer
59. Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab
    Ying Zhang, Shanshan Wu, Xinlei Zhuang, Gaoqi Weng, Jiansheng Fan, Xiaoyue Yang, Yingchun Xu, Liqiang Pan, Tingjun Hou, Zhan Mei Zhou et al. · 2019 · OncoTargets and Therapy
60. Precision medicine and personalized breast cancer: combination pertuzumab therapy
    Don Steven Dizon, Kerry Reynolds, Sasmit Sarangi, Aditya Bardia · 2014 · Pharmacogenomics and Personalized Medicine
61. PTEN deletion is rare but often homogeneous in gastric cancer
    Sormeh Mina, Benjamin A. Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob Robert Izbicki, Andreas Holger Marx et al. · 2012 · Journal of Clinical Pathology
62. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review
    Yimin Lu, Feng Cheng, Lisong Teng · 2016 · Scientific Reports
63. UVB suppresses PTEN expression by upregulating miR-141 in HaCaT cells
    Wei Li, Di Wu, Lijuan Hua, Bingrong Zhou, Ze Guo, Dan Luo · 2011 · Journal of Biomedical Research
64. BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
    Davide Zecchin, Valentina Boscaro, Enzo Médico, Ludovic Barault, Miriam Martini, Sabrina Arena, Carlotta Cancelliere, Alice Bartolini, Emily Hannah Crowley, Alberto Bardelli et al. · 2013 · Molecular Cancer Therapeutics
65. Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer
    Ali Mussa, Nor Hayati Ismail, Mahasin Hamid, Mohammad A. I. Al-Hatamleh, Anthony J. Bragoli, Khalid Hajissa, Noor Fatmawati Mokhtar, Rohimah Mohamud, Vuk Uskoković, Rosline Hassan · 2024 · Journal of Experimental & Clinical Cancer Research
66. The role of PTEN as a cancer biomarker
    Nuala McCabe, Kevin M. Prise, Richard D. Kennedy · 2016 · Oncoscience
67. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
    Nermine H. Zakaria, Doaa Ibrahim Hashad, Marwa H. Saied, Neamat Hegazy, Alyaa Elkayal, Eman Tayae · 2023 · Human Genomics
68. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
    Alessandra Fabi, Marcella Mottolese, Oreste Segatto · 2014 · Journal of Molecular Medicine
69. Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
    Yong Sang Hong, Jihun Kim, Eirini Pectasides, Cameron Fox, Seungwoo Hong, Qiuping Ma, Gabrielle S. Wong, Shouyong Peng, Matthew D. Stachler, Aaron R. Thorner et al. · 2014 · PLoS ONE
70. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
    Ashok K. Chakraborty, Cynthia A. Zerillo, Michael P. DiGiovanna · 2015 · Breast Cancer Research and Treatment
71. An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Francisco J. Esteva, Sandra X. Franco, Maura K. Hagan, Abenaa M. Brewster, Robert A. Somer, Will Williams, Allison M. Florance, Simon Turner, Steven Stein, Alejandra Perez · 2013 · The Oncologist
72. Monitoring Trastuzumab Resistance and Cardiotoxicity
    Milos Dokmanovic, Wen Jin Wu · 2015 · Advances in clinical chemistry
73. Molecular correlates of invasion pattern in HPV‐associated endocervical adenocarcinoma: emergence of two distinct risk‐stratified tiers
    Aarti E. Sharma, Anjelica Hodgson, Brooke E. Howitt, Ekaterina Olkhov‐Mitsel, Bojana Djordevic, Kay J. Park, Marisa R. Nucci, Carlos Parra‐Herran · 2023 · Histopathology
74. PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
    Daphne Gschwantler‐Kaulich, Yen Y. Tan, Eva‐Maria Fuchs, Gernot Hudelist, Wolfgang J. Köstler, Reiner Angelika, Carmen Leser, Mohamed Mamdouh Salama, Johannes Attems, Christine Deutschmann et al. · 2017 · PLoS ONE
75. An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors
    Pietro Asproni, Francesca Millanta, Lorenzo Ressel, Fabio Podestà, Francesca Parisi, Iacopo Vannozzi, Alessandro Poli · 2021 · Animals
76. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello · 2022 · Journal of Personalized Medicine
77. Involvement of microRNAs in HER2 signaling and trastuzumab treatment
    Ling Mao, Aijun Sun, Jian-zhong Wu, Jinhai Tang · 2016 · Tumor Biology
78. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
    Ashok K. Chakraborty, Christos Hatzis, Michael P. DiGiovanna · 2017 · Breast Cancer Research and Treatment
79. New developments in the treatment of HER2-positive breast cancer
    Rita Nahta · 2012 · Breast Cancer Targets and Therapy
80. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies
    Francisco J. Esteva, Elena Katz · 2024 · JCO Oncology Practice
81. Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication
    Aisha Sultana, Romana Idress, Zulfiqar Ali Naqvi, Iqbal Azam, Shaista Masood Khan, Anwar Ali Siddiqui, El–Nasir Lalani · 2014 · Translational Oncology
82. Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer
    Kerem Okutur, Nuray Başsülü, Levent Dalar, Kübra Aydın, Mustafa Bozkurt, Kezban Nur Pilancı, Gülen Doğusoy, C. Tecimer, Nil Molinas Mandel, Gökhan Demir · 2015 · Asian Pacific Journal of Cancer Prevention
83. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
    Qiong Lu, Lingfei Wang, Yajun Zhang, Xiaojie Yu, Chao Wang, Huajing Wang, Yang� Yang, Xiaodan Chong, Tian Xia, Yanchun Meng et al. · 2016 · Oncotarget
84. RETRACTED ARTICLE: LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN
    Huixian Zhang, Hao Zhang, Xingya Li, Siyuan Huang, Qianqian Guo, Di Geng · 2021 · Cancer Cell International · Retracted
85. PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
    David W. Cescon, Philippe Lucien Bedard · 2015 · Journal of Clinical Oncology
86. Phosphatase and Tensin Homolog Deficiency and Resistance to Trastuzumab and Chemotherapy
    Brent Neil Rexer, Yu Shyr, Carlos L. Arteaga · 2013 · Journal of Clinical Oncology
87. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi, Naoki Kanomata, Tetsumasa Yamashita, Toshiro Shimo, Akiko Mizutoh, Takuya Moriya, Hiroshi Sonoo · 2013 · Breast Cancer
88. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Lillian Mary Smyth, Kelsey R. Monson, Komal L. Jhaveri, Alexander Edward Dela Cruz Drilon, Bob T. Li, Wassim M. Abida, Gopa Iyer, John F. Gerecitano, Mrinal M. Gounder, James J. Harding et al. · 2017 · Investigational New Drugs
89. Precise Immunodetection of PTEN Protein in Human Neoplasia.
    R. Pulido, J. Mingo, A. Gaafar, C. Nunes-Xavier, S. Luna, Leire Torices, J. Angulo, J. López · 2019 · Cold Spring Harbor Perspectives in Medicine
90. Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer
    Huayan Ren, Jian Wang, Fan Yang, Xiaoli Zhang, Ai-Lian Wang, Li-Li Sun, Kexin Diao, Enhua Wang, Xiaoyi Mi · 2015 · Oncotarget
91. Everolimus and Its Role in Hormone-Resistant and Trastuzumab-Resistant Metastatic Breast Cancer
    Sara Keck, Alexa Glencer, Hope S. Rugo · 2012 · Future Oncology
92. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3′-kinase pathway alterations might be associated with favorable prognosis
    Ying Dong, Xi Yang, Oscar Gee‐Wan Wong, Xiaoming Zhang, Ying Liang, Ying Zhang, Wei Wong, Lin Nong, Qinping Liao, Ting Li · 2011 · Human Pathology
93. Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development
    Kirsty R. Greenow, Matthew John Smalley · 2015 · Current Protocols in Pharmacology
94. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer
    Helen Creedon, Lucy A Balderstone, Morwenna Muir, Jozef Balla, Laura Gómez-Cuadrado, Natasha Tracey, Joseph F. Loane, Teresa C. M. Klinowska, William J. Muller, Valerie G. Brunton · 2015 · Disease Models & Mechanisms
95. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
    Lingfei Wang, Xiaojie Yu, Chao Wang, Shujun Pan, Beibei Liang, Yajun Zhang, Xiaodan Chong, Yanchun Meng, Jian Dong, Yirong Zhao et al. · 2017 · Oncotarget
96. Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect
    Manni Wang, Yuzhu Hu, Ting Yu, Xuelei Ma, Xiawei Wei, Yuquan Wei · 2018 · Cancer Letters
97. Circulating and Endometrial Tissue microRNA Markers Associated with Endometrial Cancer Diagnosis, Prognosis, and Response to Treatment
    Sergio Antonio Oropeza-de Lara, Idalia Garza Veloz, Bertha Berthaúd-González, Margarita L. Martínez‐Fierro · 2023 · Cancers
98. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    Deniz Güncel Tural, Süheyla Serdengeçti, Fuat Hulusi Demirelli, Tulin Kilicaslan Ozturk, Şennur İlvan, Hande Turna, Mustafa Özgüroğlu, Evin Büyükünal · 2014 · British Journal of Cancer · Retracted
99. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights
    Lucia Da Ros, A. Moretti, Patrizia Querzoli, Massimo Pedriali, Laura Lupini, Cristian Bassi, Paolo Carcoforo, Massimo Negrini, Antonio Frassoldati · 2018 · Clinical Breast Cancer
100. The evolving role of receptors as predictive biomarkers for metastatic breast cancer
     Carlos Martínez-Pérez, Arran Turnbull, J. Michael Dixon · 2018 · Expert Review of Anticancer Therapy